StreetAlpha.app
Home › Stocks › BDTX

Black Diamond Therapeutics, Inc. (BDTX)

Healthcare
$1.44
▼ −5.88%
LAST CLOSE · NOV 17

Black Diamond Therapeutics develops cancer drugs that target families of related gene mutations in patients with tumors. It last closed at $1.44 on Nov 17, down 5.88% on the day.

AI Auto Pilots
Is BDTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$44.1M
−305.0% vs a year ago
EPS (diluted)
−$0.76
−305.4% vs a year ago
Valuation
Market cap
$82.8M
57.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$15.1M
At Sep 30
Shareholder equity
$88.1M
Shares outstanding
57.5M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $70.0M$70.0MFY2025

From BDTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated BDTX in the past 90 days, not enough for a consensus
Average 12-month target
$11.00
▲ 663.9% upside

Based on 1 analyst who set a price target on BDTX in the past 90 days. The average target is $11.00, with a high of $11.00 and a low of $11.00, compared with the last close of $1.44.

Low $11.00Avg $11.00High $11.00
Blue marker: last close $1.44
Highest target$11.00
Average target$11.00
Lowest target$11.00
Latest rating changes
HC Wainwright & Co.Reiterated
Oct 29Buy$11
StifelReinstated
Oct 16Buy$8
Raymond JamesReinstated
Jul 1Buy$11
DateFirmActionRatingPrice target
Oct 29HC Wainwright & Co.ReiteratedBuy$11
Oct 16StifelReinstatedBuy$8
Jul 1Raymond JamesReinstatedBuy$11
Loading…

Technical Analysis

BDTX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 21% below its 20 day and 27% below its 50 day average. It is 48% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the 52 week low at $1.39, and the nearest resistance the Pivot R1 at $1.50.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.9%/day
Key levels
$4.2052 week high+191.7%
$2.14200 day average+48.6%
$1.89100 day average+31.3%
$1.87Swing high (Oct 12)+29.9%
$1.8350 day average+27.1%
$1.7420 day average+20.8%
$1.50Pivot R1+4.2%
$1.44Pivot+0.0%
$1.44Last close
$1.3952 week low−3.5%
$1.39Pivot S1−3.5%
Indicators
RSI (14)37.32Weak, oversold below 30Neutral
MACD-0.10Below its signal lineBearish
Stochastic11.9Near the bottom of its rangeOversold
ADX (14)18.5No clear trend
Williams %R-91.3Oversold below −80, overbought above −20Oversold
CCI (20)-157.9Oversold below −100, overbought above 100Oversold
Rate of change−20.4%Change over 10 sessionsBearish
ATR (14)$0.14Typical daily range, 9.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BDTX

What happened before

See how BDTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow BDTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How BDTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in BDTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

BDTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲62 buying vs 39 selling
  • ▲Held by funds +4.9 pts
  • ▲Funds holding +14
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding11096+14.6%
In funds' top 1000–
Held by funds65.8%61.0%+4.9 pts
New / increased24 / 3825 / 35+3.3%
Reduced / sold out28 / 1124 / 32−30.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BDTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BDTX is in one of them and how their past BDTX trades turned out.

BDTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BDTX in an article yet. Here's the latest on the wider market.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a drug developer based in Cambridge, Massachusetts. It develops cancer medicines designed to block families of related gene mutations rather than a single mutation, aiming to treat patients whose tumors have limited treatment options. Its lead candidate, silevertinib, is being tested in patients with lung cancer and brain tumors. The company has also licensed another candidate to Servier, which is developing it for cancer and genetic diseases.

Headquarters
Cambridge, MA